Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review
2024
Anti-inflammatory effects of GLP-1 in coronary artery disease
publication
Evidence: moderate
Author Information
Author(s): Skrobucha Alicja, Pindlowski Patryk, Krajewska Natalia, Grabowski Marcin, Jonik Szymon
Primary Institution: Medical University of Warsaw
Hypothesis
What is the potential relationship between the anti-inflammatory effects of GLP-1 and coronary artery disease?
Conclusion
GLP-1 has anti-inflammatory properties that may help in the prevention and treatment of coronary artery disease.
Supporting Evidence
- GLP-1 receptor activation can inhibit atherosclerosis through regulation of inflammatory processes.
- GLP-1 has been shown to improve endothelial function in patients with coronary artery disease.
- Studies indicate that GLP-1 receptor agonists may reduce systemic inflammation.
- Animal studies demonstrate that GLP-1 can stabilize atherosclerotic plaques.
Takeaway
GLP-1 can help reduce inflammation in the heart, which is important for people with heart disease.
Methodology
This review summarizes findings from various studies on the effects of GLP-1 on inflammation and coronary artery disease.
Limitations
Human studies are limited by small sample sizes and often lack randomization.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website